Newsroom
Newsroom
Industry News
The objectives of this Phase I project will be to develop engineered yeast strains that produce high levels of natural and non-natural noscapinoids secoberberines and...
Industry News
Until now, much of the medicines we use to treat dire illnesses have been derived from plants. But that means we are dependent on natural...
Industry News
Early this year, synthetic biologist Christina Smolke was in a dead-heat race with a handful of other labs to engineer a yeast strain capable of...
Industry News
Over the past several months, scientists from around the world have published bits and pieces of a fascinating feat: In an effort to create pain...
Industry News
The objectives of this Phase I project will be to develop engineered yeast strains that produce high levels of natural and non-natural noscapinoids secoberberines and...
Industry News
Until now, much of the medicines we use to treat dire illnesses have been derived from plants. But that means we are dependent on natural...
Industry News
Early this year, synthetic biologist Christina Smolke was in a dead-heat race with a handful of other labs to engineer a yeast strain capable of...
Industry News
Over the past several months, scientists from around the world have published bits and pieces of a fascinating feat: In an effort to create pain...